Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uprosertib - Laekna Therapeutics

Next Previous
Drug Profile

Uprosertib - Laekna Therapeutics

Alternative Names: GSK-2141795; GSK-2141795C; GSK-795; LAE 003; UPB 795

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Dana-Farber Cancer Institute; Laekna Therapeutics; National Cancer Institute (USA); National Comprehensive Cancer Network; Novartis Oncology; University of California at San Francisco
  • Class Amides; Antineoplastics; Furans; Pyrazoles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cervical cancer; Endometrial cancer; Hereditary haemorrhagic telangiectasia; Lymphoma; Malignant melanoma; Multiple myeloma; Ovarian cancer; Proteus syndrome; Solid tumours; Triple negative breast cancer; Uveal melanoma

Most Recent Events

  • 24 Sep 2025 Discontinued - Phase-I for Hereditary haemorrhagic telangiectasia in China (PO) (Laekna Therapeutics pipeline, September 2025)
  • 24 Sep 2025 Discontinued - Phase-I for Proteus syndrome in China (PO) (Laekna Therapeutics pipeline, September 2025)
  • 05 Apr 2024 Efficacy and pharmacodynamics data from a phase II trial in Triple-negative-breast-cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top